STING Agonist Compounds for Stronger Type I Interferon Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing STING agonists have shown limited efficacy in clinical trials for treating cellular proliferative disorders such as cancer, and there is a need for novel compounds that can effectively induce a STING-mediated immune response to combat both foreign pathogens and cellular damage.
Innovation Solution
Development of novel STING agonist compounds represented by Formulas I, II, and III, along with their pharmaceutically acceptable salts, solvates, and stereoisomers, which can induce STING-dependent type I interferon production and cytokine production, potentially enhancing immune responses against cancer and other disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing STING agonists are used to induce immune response, then immune activation is achieved, but clinical efficacy is limited
Solution Approach 1:
The patent applies parameter changes by systematically modifying chemical parameters of STING agonist compounds, including variations in cyclic dinucleotide structures, substitution patterns, and molecular configurations. These parameter changes aim to optimize immune activation efficacy while managing structural complexity, resulting in compounds with improved clinical potential compared to existing agonists.
2Quantity of substance
If novel STING agonist compounds are developed to enhance immune response, then type I interferon production is increased, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the STING agonist compounds into modular components, including cyclic dinucleotide cores with variable substitution groups. This segmentation allows systematic optimization of interferon-inducing activity through combinatorial chemistry approaches, enabling enhanced type I interferon production while managing molecular complexity through structured design.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as cyclic ring structures, substituent types and positions, and molecular stereochemistry. These controlled parameter changes enable optimization of interferon production levels while maintaining manageable compound complexity through rational molecular design.
3Reliability
If STING agonists are used to treat cellular proliferative disorders, then anti-cancer activity is induced, but treatment effectiveness is insufficient
Solution Approach 1:
The patent applies composite materials principles by creating STING agonist compounds with composite molecular structures that combine cyclic dinucleotide cores with diverse substitution groups. These composite structures are designed to achieve superior anti-cancer activity through enhanced immune activation, addressing the insufficiency of existing single-structure agonists in treating cellular proliferative disorders.
Data Source
AI summary
The present disclosure is related to STING agonists, pharmaceutical compositions thereof, and the use of the agonists and pharmaceutical compositions to induce a STING-mediated immune response and/or to treat diseases and disorders mediated by STING, such as cellular proliferative disorders, including, but not limited to, cancer.